Novavax (NASDAQ:NVAX) Receives Sell (D+) Rating from Weiss Ratings

Key Points

• Novavax's stock has received a "sell (D+)" rating from Weiss Ratings, with an average rating of "Hold" from analysts.
• The company reported a negative revenue trend, with a 42.4% year-over-year decline in revenue, despite beating earnings expectations in the last quarter.
• Institutional investors hold approximately 53.04% of Novavax's stock, indicating a significant interest from hedge funds in the company's performance.

Novavax (NASDAQ:NVAX - Get Free Report)'s stock had its "sell (d+)" rating reiterated by investment analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

NVAX has been the topic of several other reports. Bank of America reaffirmed an "underperform" rating and issued a $7.00 price objective (down from $9.00) on shares of Novavax in a research note on Wednesday, August 20th. Citigroup assumed coverage on Novavax in a research note on Tuesday, June 17th. They issued a "sell" rating and a $6.00 price objective on the stock. Finally, HC Wainwright assumed coverage on Novavax in a research note on Thursday, August 28th. They issued a "buy" rating and a $10.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $14.29.

Novavax Stock Down 3.5%

NVAX stock opened at $8.90 on Wednesday. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.36 and a quick ratio of 2.34. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of 3.90, a PEG ratio of 0.12 and a beta of 2.74. The business's fifty day moving average price is $8.26 and its two-hundred day moving average price is $7.27. Novavax has a fifty-two week low of $5.01 and a fifty-two week high of $13.35.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.69. Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.The company had revenue of $239.24 million for the quarter, compared to analysts' expectations of $149.19 million. During the same quarter last year, the business earned $0.99 earnings per share. Novavax's revenue was down 42.4% on a year-over-year basis. On average, equities analysts anticipate that Novavax will post -1.46 earnings per share for the current year.

Institutional Trading of Novavax

Hedge funds have recently made changes to their positions in the company. Bayforest Capital Ltd acquired a new stake in shares of Novavax during the first quarter valued at about $404,000. Kingstone Capital Partners Texas LLC bought a new position in shares of Novavax during the second quarter worth about $1,016,000. Park West Asset Management LLC bought a new position in shares of Novavax during the first quarter worth about $16,210,000. Rhumbline Advisers raised its position in shares of Novavax by 3.3% during the first quarter. Rhumbline Advisers now owns 215,413 shares of the biopharmaceutical company's stock worth $1,381,000 after acquiring an additional 6,949 shares during the last quarter. Finally, Entropy Technologies LP bought a new position in shares of Novavax during the first quarter worth about $191,000. 53.04% of the stock is owned by institutional investors and hedge funds.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.